Sodium zirconium cyclosilicate is an orally administered, non-absorbed, novel, inorganic microporous zirconium silicate compound, is a highly selective cation exchanger that selectively removes excess K+ in vivo. Sodium zirconium cyclosilicate can be used in research of chronic kidney disease (CKD)[1][2].
Sodium zirconium cyclosilicate (ZS-9) is an inorganic cation exchange crystalline compound that has a high capacity to selectively entrap monovalent cations, specifically excess K+ and ammonium ions. Sodium zirconium cyclosilicate has the exchange capacities for the divalent ions Ca2+ and Mg2+ are below 0.05 mEq/g, and a >25-fold selectivity for K+ over either Ca2+ or Mg2+[1].
Sodium zirconium cyclosilicate (ZS-9; 2-6 g/kg; p.o.; daily, for 5 d) is a recovery in feces of Sprague-Dawley rats and can efficient uptake and removal of potassium ions[2].
| Animal Model: | Sprague-Dawley rats[2] |
| Dosage: | 2, 4, and 6 g/kg |
| Administration: | Oral administration; daily, for 5 days |
| Result: | Had 99% fecal recovery in rats. Uptake and removal of potassium ions in a dose-dependent manner. |
[1]. Stavros F, et, al. Characterization of structure and function of ZS-9, a K+ selective ion trap. PLoS One. 2014 Dec 22;9(12):e114686.
[2]. Ash SR, et, al. A phase 2 study on the treatment of perkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient. Kidney Int. 2015 Aug;88(2):404-11.